INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells
Retrieved on:
Wednesday, August 25, 2021
Company, Lymphoma, Ovarian cancer, Private Securities Litigation Reform Act, Inflammation, Phenotype, Cancer, Gene, TNF, U.S. Securities and Exchange Commission, GLOBE, Multiple myeloma, Survival, Treatment, NK, Research, Natural killer cell, Disease, NKG2D, Marketing, Cell, MDS, CRS, NASDAQ, Cytokine release syndrome, Patient, Cytolysis, Toxicity, Cytokine, NASH, Breast cancer, COVID-19, Leukemia, Security (finance), Medical imaging, Pharmaceutical industry, Vaccine
Boca Raton, FL, Aug. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted by previously published in vitro experiments.
Key Points:
- NK cells need multiple activating signals to progress from a resting state to the triggering of cytolysis and cytokine secretion.
- Preliminary data from the first patient shows that formation of mlNK cells can be achieved in vivo and without toxicity.
- INKmune therapy cause proliferation of NK cells with a doubling of the number of peripheral blood NK cell numbers on day 8.
- More than 80% of the activated NK cells expressed markers associated with a memory-like NK cell (CD57++, NKG2D+, NKG2A-ve, NKp46-ve).